Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 13NIH 8INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 39Breast Neoplasms 24Neoplasms 12Prostatic Neoplasms 11Triple Negative Breast Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Carcinoma, Ovarian Epithelial 6Stomach Neoplasms 5Metastatic Castration-resistant Prostate Cancer 5Fanconi Anemia, Complementation Group D1 5Small Cell Lung Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumors 4Solid Tumors 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Colorectal Neoplasms 2Carcinoma 2Advanced Solid Tumours 2Advanced Solid Tumor 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Metastatic Breast Cancer 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Diseases 1Platinum-sensitive Ovarian Cancer 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1

Interventions

Paclitaxel 47Carboplatin 38liposomal doxorubicin 25Bevacizumab 23Gemcitabine 18Topotecan 15pembrolizumab 14mirvetuximab soravtansine 11rucaparib 8niraparib 7Cisplatin 71-dodecylpyridoxal 7trebananib 6Drug Therapy 6130-nm albumin-bound paclitaxel 6Nivolumab 5Cyclophosphamide 5cemiplimab 4sarilumab 3relacorilant 3pazopanib 3oregovomab 3olaparib 3Doxorubicin 3Docetaxel 3Albumin-Bound Paclitaxel 3tocilizumab 2seribantumab 2phenoxodiol 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Fallopian Tube Neoplasms × olaparib × Clear all
NCT06915025 2026-06-02

OVATION-3

Imunon

Phase 3 Recruiting
500 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07024784 2026-06-02

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

AbbVie

Phase 2 Recruiting
377 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms

NCT03740165 2026-05-04

KEYLYNK-001

Merck Sharp & Dohme LLC

Phase 3 Completed
1,367 enrolled 29 charts
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡